AR090037A1 - Derivados de tieno y/o furo-pirimidinas y piridinas inhibidores de los canales de potasio - Google Patents
Derivados de tieno y/o furo-pirimidinas y piridinas inhibidores de los canales de potasioInfo
- Publication number
- AR090037A1 AR090037A1 ARP120104296A ARP120104296A AR090037A1 AR 090037 A1 AR090037 A1 AR 090037A1 AR P120104296 A ARP120104296 A AR P120104296A AR P120104296 A ARP120104296 A AR P120104296A AR 090037 A1 AR090037 A1 AR 090037A1
- Authority
- AR
- Argentina
- Prior art keywords
- optionally substituted
- alkyl
- thieno
- pyrimidin
- piperidin
- Prior art date
Links
- RQMWVVBHJMUJNZ-UHFFFAOYSA-N 4-chloropyridin-2-amine Chemical compound NC1=CC(Cl)=CC=N1 RQMWVVBHJMUJNZ-UHFFFAOYSA-N 0.000 title 1
- 102000004257 Potassium Channel Human genes 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 108020001213 potassium channel Proteins 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 31
- 125000000547 substituted alkyl group Chemical group 0.000 abstract 12
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 11
- 125000005346 substituted cycloalkyl group Chemical group 0.000 abstract 8
- -1 tetrahydro-1,3-oxazinyl Chemical group 0.000 abstract 8
- 125000000217 alkyl group Chemical group 0.000 abstract 7
- 125000002947 alkylene group Chemical group 0.000 abstract 7
- 125000001072 heteroaryl group Chemical group 0.000 abstract 6
- 125000003107 substituted aryl group Chemical group 0.000 abstract 5
- 125000001475 halogen functional group Chemical group 0.000 abstract 4
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 abstract 4
- 125000005415 substituted alkoxy group Chemical group 0.000 abstract 4
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 abstract 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 3
- 125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 abstract 2
- 229910003827 NRaRb Inorganic materials 0.000 abstract 2
- 229910006074 SO2NH2 Inorganic materials 0.000 abstract 2
- 239000002253 acid Substances 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 229910052760 oxygen Inorganic materials 0.000 abstract 2
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 abstract 2
- 229910052717 sulfur Inorganic materials 0.000 abstract 2
- JLOIWHWGPIRXBQ-UHFFFAOYSA-N 1-(5-methylthieno[2,3-d]pyrimidin-4-yl)piperidin-4-amine Chemical compound C=12C(C)=CSC2=NC=NC=1N1CCC(N)CC1 JLOIWHWGPIRXBQ-UHFFFAOYSA-N 0.000 abstract 1
- VLCVHCJARZAQOT-UHFFFAOYSA-N 1-(6-methyl-5-phenylthieno[2,3-d]pyrimidin-4-yl)piperidin-4-amine Chemical compound C=12C(C=3C=CC=CC=3)=C(C)SC2=NC=NC=1N1CCC(N)CC1 VLCVHCJARZAQOT-UHFFFAOYSA-N 0.000 abstract 1
- ZCGQJNHNULHCGN-UHFFFAOYSA-N 1-(6-methyl-5-phenylthieno[2,3-d]pyrimidin-4-yl)piperidin-4-one Chemical compound C=12C(C=3C=CC=CC=3)=C(C)SC2=NC=NC=1N1CCC(=O)CC1 ZCGQJNHNULHCGN-UHFFFAOYSA-N 0.000 abstract 1
- WPZQFXGPJKULGO-UHFFFAOYSA-N 1-[5-(4-bromophenyl)thieno[2,3-d]pyrimidin-4-yl]piperidin-4-amine Chemical compound C1CC(N)CCN1C1=NC=NC2=C1C(C=1C=CC(Br)=CC=1)=CS2 WPZQFXGPJKULGO-UHFFFAOYSA-N 0.000 abstract 1
- OVUIZPTUHKPUQH-UHFFFAOYSA-N 1-[5-(4-methylphenyl)thieno[2,3-d]pyrimidin-4-yl]piperidin-4-amine Chemical compound C1=CC(C)=CC=C1C1=CSC2=NC=NC(N3CCC(N)CC3)=C12 OVUIZPTUHKPUQH-UHFFFAOYSA-N 0.000 abstract 1
- JPDCBVOCAONAFB-UHFFFAOYSA-N 1-[5-(4-methylphenyl)thieno[2,3-d]pyrimidin-4-yl]piperidin-4-one Chemical compound C1=CC(C)=CC=C1C1=CSC2=NC=NC(N3CCC(=O)CC3)=C12 JPDCBVOCAONAFB-UHFFFAOYSA-N 0.000 abstract 1
- MJILZRSAPALVKX-UHFFFAOYSA-N 1-phenylmethoxy-3-[[1-(5-phenylthieno[2,3-d]pyrimidin-4-yl)piperidin-4-yl]amino]propan-2-ol Chemical compound C=1C=CC=CC=1COCC(O)CNC(CC1)CCN1C(C1=2)=NC=NC=2SC=C1C1=CC=CC=C1 MJILZRSAPALVKX-UHFFFAOYSA-N 0.000 abstract 1
- NOWQHVUBAUZKBW-UHFFFAOYSA-N 2-[[1-[5-(4-bromophenyl)thieno[2,3-d]pyrimidin-4-yl]piperidin-4-yl]amino]cyclohexan-1-ol Chemical compound OC1CCCCC1NC1CCN(C=2C=3C(C=4C=CC(Br)=CC=4)=CSC=3N=CN=2)CC1 NOWQHVUBAUZKBW-UHFFFAOYSA-N 0.000 abstract 1
- AJFKKJXKBSDZIM-UHFFFAOYSA-N 2-benzyl-5-methyl-4-morpholin-4-ylthieno[2,3-d]pyrimidine-6-carbonitrile Chemical compound N=1C(N2CCOCC2)=C2C(C)=C(C#N)SC2=NC=1CC1=CC=CC=C1 AJFKKJXKBSDZIM-UHFFFAOYSA-N 0.000 abstract 1
- RXLPRZHHAKTOIY-UHFFFAOYSA-N CC1=CC=C(C=C1)C2=CSC3=NC=NC(=C23)N4CCC(CC4)NC(=O)O Chemical compound CC1=CC=C(C=C1)C2=CSC3=NC=NC(=C23)N4CCC(CC4)NC(=O)O RXLPRZHHAKTOIY-UHFFFAOYSA-N 0.000 abstract 1
- 229910006069 SO3H Inorganic materials 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000003725 azepanyl group Chemical group 0.000 abstract 1
- 125000002393 azetidinyl group Chemical group 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 125000003106 haloaryl group Chemical group 0.000 abstract 1
- 125000004366 heterocycloalkenyl group Chemical group 0.000 abstract 1
- 125000005885 heterocycloalkylalkyl group Chemical group 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 125000002757 morpholinyl group Chemical group 0.000 abstract 1
- 125000005968 oxazolinyl group Chemical group 0.000 abstract 1
- 125000003386 piperidinyl group Chemical group 0.000 abstract 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 125000005017 substituted alkenyl group Chemical group 0.000 abstract 1
- 125000006008 trihaloethoxy group Chemical group 0.000 abstract 1
- 125000006004 trihaloethyl group Chemical group 0.000 abstract 1
- 125000004951 trihalomethoxy group Chemical group 0.000 abstract 1
- 125000004953 trihalomethyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Reproductive Health (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1119703.5A GB201119703D0 (en) | 2011-11-15 | 2011-11-15 | Compounds |
GBGB1214250.1A GB201214250D0 (en) | 2012-08-09 | 2012-08-09 | Compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
AR090037A1 true AR090037A1 (es) | 2014-10-15 |
Family
ID=47222145
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP120104296A AR090037A1 (es) | 2011-11-15 | 2012-11-14 | Derivados de tieno y/o furo-pirimidinas y piridinas inhibidores de los canales de potasio |
Country Status (15)
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RS57250B1 (sr) | 2013-06-06 | 2018-07-31 | Astellas Pharma Inc | Jedinjenje benzotiofena |
FR3015483B1 (fr) * | 2013-12-23 | 2016-01-01 | Servier Lab | Nouveaux derives de thienopyrimidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
RU2545758C1 (ru) * | 2014-03-20 | 2015-04-10 | Общество с ограниченной ответственностью "Алион" | Бициклические пиримидины или их фармацевтически приемлемые соли-активаторы антиоксидантной программы и их применение в качестве цитопротекторов |
USRE49687E1 (en) | 2014-09-09 | 2023-10-10 | The Regents Of The University Of Michigan | Thienopyrimidine and thienopyridine compounds and methods of use thereof |
WO2016197027A1 (en) | 2015-06-04 | 2016-12-08 | Kura Oncology, Inc. | Methods and compositions for inhibiting the interaction of menin with mll proteins |
TWI703150B (zh) | 2015-06-04 | 2020-09-01 | 美商庫拉腫瘤技術股份有限公司 | 用於抑制menin及mll蛋白之交互作用的方法及組合物 |
FR3037959B1 (fr) * | 2015-06-23 | 2017-08-04 | Servier Lab | Nouveaux derives bicycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
FR3037956B1 (fr) * | 2015-06-23 | 2017-08-04 | Servier Lab | Nouveaux derives d'acide amine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
FR3037957B1 (fr) * | 2015-06-23 | 2019-01-25 | Les Laboratoires Servier | Nouveaux derives d'hydroxyester, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
FR3037958B1 (fr) * | 2015-06-23 | 2019-01-25 | Les Laboratoires Servier | Nouveaux derives d'hydroxy-acide, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
CN109311868B (zh) | 2015-12-22 | 2022-04-01 | 尚医治疗有限责任公司 | 用于治疗癌症和炎性疾病的化合物 |
HRP20230537T1 (hr) | 2016-03-16 | 2023-08-04 | Kura Oncology, Inc. | Supstituirani derivati tieno[2,3-d]pirimidina kao inhibitori za menin-mll i postupci za uporabu |
CN109640987B (zh) | 2016-03-16 | 2022-12-02 | 库拉肿瘤学公司 | Menin-mll的桥联双环抑制剂及使用方法 |
CN106727587A (zh) * | 2016-11-28 | 2017-05-31 | 李娜 | 一种治疗心律失常的药物组合物 |
WO2018125810A1 (en) | 2016-12-28 | 2018-07-05 | Dart Neuroscience, Llc | Substituted pyrazolopyrimidinone compounds as pde2 inhibitors |
EA038388B1 (ru) * | 2017-01-16 | 2021-08-19 | Кура Онколоджи, Инк. | Замещенные ингибиторы менина-mll и способы применения |
US11944627B2 (en) | 2017-03-24 | 2024-04-02 | Kura Oncology, Inc. | Methods for treating hematological malignancies and Ewing's sarcoma |
WO2018226976A1 (en) | 2017-06-08 | 2018-12-13 | Kura Oncology, Inc. | Methods and compositions for inhibiting the interaction of menin with mll proteins |
EP3642209B1 (en) | 2017-06-21 | 2023-11-29 | Shy Therapeutics LLC | Compounds that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease |
CN111344281B (zh) * | 2017-08-14 | 2023-11-14 | 阿塞西翁制药公司 | 取代苯并咪唑类的钾通道抑制剂 |
WO2019060365A1 (en) | 2017-09-20 | 2019-03-28 | Kura Oncology, Inc. | SUBSTITUTED MÉNINE-MLL INHIBITORS AND METHODS OF USE |
MX2020005447A (es) | 2017-11-27 | 2020-12-03 | Dart Neuroscience Llc | Compuestos de furanopirimidina sustituida como inhibidores de pde1. |
CN108117556A (zh) * | 2018-01-15 | 2018-06-05 | 王山川 | 一种细胞周期检查点激酶1抑制剂的合成方法 |
WO2020085504A1 (ja) | 2018-10-26 | 2020-04-30 | 大鵬薬品工業株式会社 | 光照射ザンドマイヤー反応を用いたクロロアゾールカルボキシレート誘導体の製造方法 |
JP7407461B2 (ja) | 2018-12-19 | 2024-01-04 | シャイ・セラピューティクス・エルエルシー | がん、炎症性疾患、ras病、及び線維性疾患の処置のためのrasスーパーファミリーと相互作用する化合物 |
US11168093B2 (en) | 2018-12-21 | 2021-11-09 | Celgene Corporation | Thienopyridine inhibitors of RIPK2 |
BR112022007783A8 (pt) | 2019-10-28 | 2023-04-11 | Merck Sharp & Dohme | Composto, composição farmacêutica, e, métodos para inibir proteína g12c de kras e para tratar câncer |
WO2021106231A1 (en) * | 2019-11-29 | 2021-06-03 | Taiho Pharmaceutical Co., Ltd. | A compound having inhibitory activity against kras g12d mutation |
WO2022194191A1 (en) * | 2021-03-16 | 2022-09-22 | Guangdong Newopp Biopharmaceuticals Co., Ltd. | Heterocyclic compounds as inhibitors of kras g12d |
JP2024511801A (ja) * | 2021-03-26 | 2024-03-15 | スミトモ ファーマ オンコロジー, インコーポレイテッド | (フロピリミジン-4-イル)ピペラジン化合物及びその使用 |
CN115006468B (zh) * | 2022-06-28 | 2023-06-06 | 西安外事学院 | 一种复方中草药生发液及制备方法 |
Family Cites Families (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4008726A1 (de) | 1990-03-19 | 1991-09-26 | Basf Ag | Thieno(2,3-d)pyrimidinderivate |
BR9101256A (pt) * | 1990-03-30 | 1991-11-05 | Dowelanco | Composto,composicao fungicida,processo fungicida,composicao inseticida ou acaricida e processo inseticida ou acaricida |
WO1998008845A1 (en) | 1996-08-27 | 1998-03-05 | Novartis Ag | Herbicidal s-substituted 1,2,4,6-thiatriazines |
WO2004011057A1 (en) | 1998-02-07 | 2004-02-05 | Advanced Cardiovascular Systems, Inc. | Perfusion dilatation catherer with expanded support coil |
JP2001097979A (ja) | 1999-07-28 | 2001-04-10 | Takeda Chem Ind Ltd | 縮合複素環化合物、その製造法および用途 |
EP1212314B1 (en) | 1999-09-17 | 2005-11-30 | Nissan Chemical Industries, Ltd. | Benzopyran derivative |
US6887870B1 (en) | 1999-10-12 | 2005-05-03 | Bristol-Myers Squibb Company | Heterocyclic sodium/proton exchange inhibitors and method |
SE9904738D0 (sv) | 1999-12-22 | 1999-12-22 | Astra Pharma Prod | Novel compounds |
DE10031585A1 (de) * | 2000-06-29 | 2002-01-10 | Merck Patent Gmbh | 2-Aminoalkyl-thieno[2,3-d]pyrimidine |
TW589305B (en) | 2001-02-14 | 2004-06-01 | Nissan Chemical Ind Ltd | 4-aminobenzopyran derivatives |
HUP0400362A3 (en) | 2001-06-25 | 2007-05-29 | Nissan Chemical Ind Ltd | Substituted benzopyran derivetives against arrhythmia |
WO2003022214A2 (en) | 2001-09-06 | 2003-03-20 | Millennium Pharmaceuticals, Inc. | Piperazine and homopiperazine compounds |
AU2002333524A1 (en) * | 2001-09-11 | 2003-03-24 | Glaxosmithkline K.K. | Furo-and thienopyrimidine derivatives as angiogenesis inhibitors |
US20040138238A1 (en) * | 2002-08-08 | 2004-07-15 | Dhanoa Dale S. | Substituted aminopyrimidine compounds as neurokinin antagonists |
ES2217956B1 (es) | 2003-01-23 | 2006-04-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de 4-aminotieno(2,3-d)pirimidin-6-carbonitrilo. |
US20050222175A1 (en) | 2004-03-31 | 2005-10-06 | Dhanoa Dale S | New piperidinylamino-thieno[2,3-D] pyrimidine compounds |
EP1641803B3 (en) | 2003-06-11 | 2010-12-08 | Xention Limited | Thienopyrimidine derivatives as potassium channel inhibitors |
GB0315950D0 (en) * | 2003-06-11 | 2003-08-13 | Xention Discovery Ltd | Compounds |
US7594219B2 (en) | 2003-07-24 | 2009-09-22 | International Business Machines Corporation | Method and apparatus for monitoring compatibility of software combinations |
TWI346112B (en) | 2004-02-25 | 2011-08-01 | Nissan Chemical Ind Ltd | Benzopyran compound |
WO2005100365A1 (ja) * | 2004-04-12 | 2005-10-27 | Sankyo Company, Limited | チエノピリジン誘導体 |
JP4955557B2 (ja) | 2004-06-10 | 2012-06-20 | ゼンション・リミテッド | カリウムチャネル阻害剤として有効なフラノピリミジン化合物 |
GB0420719D0 (en) | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
KR20140008471A (ko) | 2004-10-21 | 2014-01-21 | 다우 아그로사이언시즈 엘엘씨 | 살진균 활성을 갖는 티에노-피리미딘 화합물 |
US7576212B2 (en) * | 2004-12-09 | 2009-08-18 | Xention Limited | Thieno[2,3-B] pyridines as potassium channel inhibitors |
JP5173429B2 (ja) * | 2004-12-09 | 2013-04-03 | ゼンション・リミテッド | 化合物 |
US7576080B2 (en) | 2004-12-23 | 2009-08-18 | Memory Pharmaceuticals Corporation | Certain thienopyrimidine derivatives as phosphodiesterase 10 inhibitors |
EP1844052A1 (en) | 2005-01-26 | 2007-10-17 | Pharmacia & Upjohn Company LLC | Thieno[2,3-d]pyrimidine compounds as inhibitors of adp-mediated platelets aggregation |
CA2602358A1 (en) | 2005-03-25 | 2006-09-28 | Pharmacia & Upjohn Company Llc | 4-piperazinnylthieno [2,3-d] pyrimidine compounds as platelet aggregation inhibitors |
EP1866317A1 (en) | 2005-03-28 | 2007-12-19 | Pharmacia & Upjohn Company LLC | 4-piperazinothieno [2, 3-d] pyrimidine compounds as platelet aggregation inhibitors |
JP2008534571A (ja) | 2005-03-28 | 2008-08-28 | ファルマシア・アンド・アップジョン・カンパニー・エルエルシー | 血小板凝集阻害物質としての4−ピペラジニルチエノ[2,3−d]ピリミジン化合物 |
CA2603041A1 (en) | 2005-03-28 | 2006-10-05 | Pharmacia & Upjohn Company Llc | 4-piperazinylthieno [2, 3-d] pyrimidine compounds as platelet aggregation inhibitors |
US20060281768A1 (en) * | 2005-06-10 | 2006-12-14 | Gaul Michael D | Thienopyrimidine and thienopyridine kinase modulators |
US20100143341A1 (en) * | 2005-06-22 | 2010-06-10 | Develogen Aktiengesellschaft | Thienopyrimidines for pharmaceutical compositions |
US7816351B2 (en) * | 2005-09-23 | 2010-10-19 | Equispharm Co., Ltd | 5,6-dimethylthieno[2,3-di] pyrimidine derivatives, the preparation method thereof and the pharmaceutical composition comprising the same for anti-virus |
WO2007056214A2 (en) * | 2005-11-02 | 2007-05-18 | Cytovia, Inc | N-alkyl-n-aryl-thienopyrimidin-r-amines and uses thereof |
GB0525164D0 (en) * | 2005-12-09 | 2006-01-18 | Xention Discovery Ltd | Compounds |
CA2651898A1 (en) * | 2006-04-07 | 2007-10-18 | Develogen Aktiengesellschaft | Thienopyrimidines having mnk1/mnk2 inhibiting activity for pharmaceutical compositions |
CN101500575A (zh) * | 2006-06-12 | 2009-08-05 | 沃泰克斯药物股份有限公司 | 可用作离子通道调控剂的噻吩并嘧啶 |
DE102006030236A1 (de) | 2006-06-30 | 2008-01-03 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Direktoxidationsbrennstoffzelle für den konvektionsfreien Transport des Brennstoffs und Verfahren zum Betreiben der Brennstoffzelle |
EP1947103A1 (en) | 2007-01-22 | 2008-07-23 | 4Sc Ag | Aryloxypropanolamines, methods of preparation thereof and use of aryloxypropanolamines as medicaments |
GB0713602D0 (en) | 2007-07-12 | 2007-08-22 | Syngenta Participations Ag | Chemical compounds |
US8193178B2 (en) * | 2007-09-14 | 2012-06-05 | Janssen Pharmaceutica Nv | Thieno- and furo-pyrimidine modulators of the histamine H4 receptor |
JP2011507910A (ja) | 2007-12-21 | 2011-03-10 | ユニバーシティー オブ ロチェスター | 真核生物の寿命を変更するための方法 |
HRP20140796T1 (hr) | 2008-02-22 | 2014-10-24 | Otsuka Pharmaceutical Co., Ltd. | Spoj benzodiazepina i farmaceutski sastav |
US20100227853A1 (en) | 2008-04-18 | 2010-09-09 | Trustees Of Boston College | Inhibitors of cyclic amp phosphodiesterases |
US7863291B2 (en) | 2008-04-23 | 2011-01-04 | Bristol-Myers Squibb Company | Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands |
WO2010023181A1 (en) * | 2008-08-26 | 2010-03-04 | Boehringer Ingelheim International Gmbh | Thienopyrimidines for pharmaceutical compositions |
TWI334124B (en) * | 2008-08-28 | 2010-12-01 | Au Optronics Corp | Display drive circuit for flat panel display and driving method for gate lines |
TWI389913B (zh) | 2008-09-08 | 2013-03-21 | Lg Life Sciences Ltd | 并合雜環化合物 |
WO2010030757A2 (en) | 2008-09-10 | 2010-03-18 | Kalypsys Inc. | Aminopyrimidine inhibitors of histamine receptors for the treatment of disease |
WO2010033127A1 (en) | 2008-09-22 | 2010-03-25 | Sionyx, Inc. | Response-enhanced monolithic-hybrid pixel |
US8993552B2 (en) | 2009-09-04 | 2015-03-31 | The Regents Of The University Of Michigan | Compositions and methods for treatment of leukemia |
KR20120099060A (ko) | 2009-10-29 | 2012-09-06 | 브리스톨-마이어스 스큅 컴퍼니 | 알파-7 니코틴성 아세틸콜린 수용체 리간드로서의 퀴누클리딘 화합물 |
US8173808B2 (en) | 2009-12-30 | 2012-05-08 | Arqule, Inc. | Substituted naphthalenyl-pyrimidine compounds |
TW201219401A (en) * | 2010-09-14 | 2012-05-16 | Lexicon Pharmaceuticals Inc | Bicyclic inhibitors of Notum Pectinacetylesterase and methods of their use |
DK2835131T3 (en) | 2010-12-14 | 2017-12-04 | Electrophoretics Ltd | Casein kinase 1 delta inhibitors (CK1 delta) |
EP2663312B1 (en) | 2011-01-10 | 2017-10-11 | Nimbus Iris, Inc. | Irak inhibitors and uses thereof |
-
2012
- 2012-11-14 AR ARP120104296A patent/AR090037A1/es unknown
- 2012-11-15 RU RU2014124101/04A patent/RU2014124101A/ru not_active Application Discontinuation
- 2012-11-15 WO PCT/GB2012/052842 patent/WO2013072694A1/en active Application Filing
- 2012-11-15 US US14/358,722 patent/US9290511B2/en not_active Expired - Fee Related
- 2012-11-15 KR KR1020147015757A patent/KR20140094603A/ko not_active Withdrawn
- 2012-11-15 EP EP12790948.9A patent/EP2780343A1/en not_active Withdrawn
- 2012-11-15 TW TW101142693A patent/TWI498331B/zh not_active IP Right Cessation
- 2012-11-15 CA CA2855346A patent/CA2855346A1/en not_active Abandoned
- 2012-11-15 IN IN1183MUN2014 patent/IN2014MN01183A/en unknown
- 2012-11-15 JP JP2014540560A patent/JP2014533259A/ja active Pending
- 2012-11-15 BR BR112014011671A patent/BR112014011671A2/pt not_active IP Right Cessation
- 2012-11-15 AU AU2012338570A patent/AU2012338570A1/en not_active Abandoned
- 2012-11-15 CN CN201280061286.3A patent/CN104011054B/zh not_active Expired - Fee Related
- 2012-11-15 MX MX2014005935A patent/MX2014005935A/es not_active Application Discontinuation
-
2014
- 2014-05-14 ZA ZA2014/03503A patent/ZA201403503B/en unknown
-
2016
- 2016-02-05 US US15/016,846 patent/US20160152634A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
TWI498331B (zh) | 2015-09-01 |
KR20140094603A (ko) | 2014-07-30 |
AU2012338570A1 (en) | 2014-07-03 |
CN104011054B (zh) | 2016-08-24 |
MX2014005935A (es) | 2014-09-04 |
CA2855346A1 (en) | 2013-05-23 |
US20160152634A1 (en) | 2016-06-02 |
NZ626199A (en) | 2015-04-24 |
JP2014533259A (ja) | 2014-12-11 |
RU2014124101A (ru) | 2015-12-27 |
CN104011054A (zh) | 2014-08-27 |
US20140371203A1 (en) | 2014-12-18 |
US9290511B2 (en) | 2016-03-22 |
IN2014MN01183A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 2015-07-03 |
EP2780343A1 (en) | 2014-09-24 |
ZA201403503B (en) | 2016-09-28 |
BR112014011671A2 (pt) | 2017-05-30 |
WO2013072694A1 (en) | 2013-05-23 |
TW201326178A (zh) | 2013-07-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR090037A1 (es) | Derivados de tieno y/o furo-pirimidinas y piridinas inhibidores de los canales de potasio | |
AR088625A1 (es) | Derivados de aril-quinolina | |
AR108388A2 (es) | Compuestos de oxazol sustituidos con indazol como inhibidores de pi3-quinasas | |
AR106945A2 (es) | Compuestos de isoindolina y composiciones farmacéuticas de los mismos | |
AR087919A1 (es) | Heterociclos biciclicos como inhibidores de irak4 | |
CO6251260A2 (es) | Derivados de bifenilo conformacionalmente restringido para uso como inhibidores del virus de la hepatitis c. | |
AR100809A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
ES2612259T3 (es) | Inhibidores de cinasa | |
AR060173A1 (es) | Derivados de piridina y de pirimidina como antagonistas del mglur2, metodos para su preparacion, composiciones farmaceuticas que los contienen y su uso en la fabricacion de medicamentos para el tratamiento de trastornos del snc. | |
CR9959A (es) | Derivados de pirazol | |
AR088029A1 (es) | Compuestos de pirimidina sustituidos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento del dolor, accidentes cerebrovasculares, epilepsia y otras enfermedades del sistema nervioso central | |
AR065322A1 (es) | 2-aminooxazolinas comoligandos de taar1 | |
AR103969A1 (es) | Inmunomoduladores | |
AR100975A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
AR099913A1 (es) | Derivados de indolizina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
AR103828A1 (es) | INHIBIDORES DEL FACTOR TRANSFORMADOR DEL CRECIMIENTO b | |
ECSP13012858A (es) | Derivados de piperidina puenteada | |
AR100807A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
AR059513A1 (es) | Derivados benzoil - piperidina como moduladores de 5ht/ d3 | |
AR100418A1 (es) | Compuestos y composiciones para inducir condrogénesis | |
AR092742A1 (es) | Piridinonas antifibroticas | |
AR085615A1 (es) | Derivados de fluoropiridinona utiles como agentes antibacterianos y composiciones farmaceuticas que los contienen | |
ES2600636T3 (es) | Spiro-[1,3]-oxazinas y spiro-[1,4]-oxazepinas como inhibidores de BACE1 y/o BACE2 | |
AR086590A1 (es) | Compuestos de ciclohexanona y herbicidas que los comprenden | |
CO6270288A2 (es) | Composicion fungicida que comprende cantidades significativamente efectivas de un derivadio de amida de acido carboxilico o su sal |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |